Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy (PF-BARNA)

BUSQUETS, JULI

Status: Not yet enrolling

Conditions: Carcinoma, Pancreatic Ductal

Treatments: Procedure: Resection; Procedure: No Resection

Study type: Observational

Funder types: Other

Identifiers

NCT05489458

HUB-BR-PDAC-2022

Details and patient eligibility

About

Radical surgical resection is the only curative treatment option for pancreatic cancer, but borderline resectable tumors have a high probability of incomplete exeresis. Although neoadjuvant therapy can improve the chances of complete exeresis, not all patients respond as expected.

Full description

Pancreatic cancer is an important cause of cancer-related death worldwide. Radical surgical resection still is the only curative treatment option today, but not all tumors are considered resectable. Among resectable tumors, some are deemed borderline and have a high probability of incomplete exeresis. Neoadjuvant therapy (NAT) can be a game-changer for borderline cases, and there is a lack of evidence on the predictive factors associated with resectability after neoadjuvant treatment.

This study aims to assess the prognostic factors for resectability and survival after NAT in type A borderline resectable pancreatic ductal adenocarcinoma patients.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients ≥18 years old.
• Both sexes.
• Diagnosed with a type A BR-PDAC between January 2010 and December 2019.
• Minimum follow-up period of 12 months.

Exclusion criteria

• Patients diagnosed with a type B or type C BR-PDAC.
• Patients diagnosed with a type A BR-PDAC who had disease progression prior to receiving NAT.

Trial design

100 participants in 2 patient groups

Exploratory Surgery with Resection

Description:

Type A BR-PDAC patients that underwent surgical exploration after neoadjuvant therapy and had their tumors resected.

Treatment:

Procedure: Resection

Exploratory Surgery without Resection

Description:

Type A BR-PDAC patients that underwent surgical exploration after neoadjuvant therapy and did not have their tumors resected.

Treatment:

Procedure: No Resection